We are a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Our lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer.
Partnerships Ascletis: license partner (denifanstat designated ASC-40 in China; FASCINATE-1 China cohort). TAPI: license to resmetirom API IP for Sagimet's evaluation/manufacture of the denifanstat + resmetirom combination
Indications
Non-cirrhotic MASH with F2-F3 fibrosis(Phase 2)
F4-stage (cirrhotic) MASH (combination with resmetirom)(Stage not disclosed)
Acne(Stage not disclosed)
FASN-dependent solid tumors(Stage not disclosed)
Status note Oral once-daily FASN inhibitor. FDA granted Breakthrough Therapy designation for non-cirrhotic MASH with F2-F3 fibrosis (supported by the Phase 2b FASCINATE-2 trial). Developing a combination of denifanstat and resmetirom (Rezdiffra) for F4 cirrhotic MASH; also evaluating FASN inhibitors in acne and FASN-dependent solid tumors.
Per-asset detail extracted from the 10-Q filed 2026-08-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.